MEDSECUREAN.COM for INDIAN PHARMACEUTICAL ALLIANCE(FORMERLY INDIAN PHARMACEUTICAL ASSOCIATION)
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 2nd Quarter - Report | Aug 12, 2024 | — | Replaced |
| 2nd Quarter - Report | Aug 12, 2024 | — | Replaced |
| 2nd Quarter - Amendment (this page) | Mar 5, 2025 | $15,000 | Yes |
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
IPA seeks to establish a U.S.-India trade partnership to de-risk the affordable medicine supply chain, including Key Starting Materials (KSMs) and Active Pharmaceutical Ingredients (APIs). This initiative aims to extend to other trusted allies, enhancing global supply chain resilience. The partnership focuses on industry sustainability, quality metrics, market demand, and boosting domestic and allied manufacturing with a suite of financial tools. Additionally, IPA seeks to advocate for middlemen reform and sustainability in the pharmaceutical sector, ensuring long-term viability and accessibility of affordable medicines.
Foreign entity interest: IPA is a trade association based in India, representing global manufacturers of both innovative and affordable medicines. These key industry players are instrumental in the U.S. healthcare market, supplying nearly 50% of the medicine for U.S. Medicare program. Also, in the top 10 therapeutic categories in the U.S., IPA member companies provide more than half of the prescriptions for five of these categories, with their market share in some categories reaching up to 60%. This significant contribution underscores IPA's crucial role as America's Medicine partner, ensuring access to affordable medications, thereby supporting America's health.
| Lobbyist | Covered position, as disclosed |
|---|---|
| KATHLEEN JAEGER New | — |
Trade (domestic/foreign) TRD
IPA champions a U.S.-India trade partnership to de-risk the affordable medicine supply chain, including Key Starting Materials (KSMs) and Active Pharmaceutical Ingredients (APIs). This initiative aims to extend to other trusted allies, enhancing global supply chain resilience. The partnership focuses on industry sustainability, quality metrics, market demand, and boosting domestic and allied manufacturing with a suite of financial tools
Foreign entity interest: IPA is a trade association based in India, representing global manufacturers of both innovative and affordable medicines.
| Lobbyist | Covered position, as disclosed |
|---|---|
| KATHLEEN JAEGER New | — |
Defense DEF
IPA champions a U.S.-India affordable medicine trade partnership to drive national security and de-risk the affordable medicine supply chain, including Key Starting Materials (KSMs) and Active Pharmaceutical Ingredients (APIs). This initiative aims to extend to other trusted allies, enhancing global supply chain resilience.
Foreign entity interest: IPA is a trade association based in India, representing global manufacturers of both innovative and affordable medicines.
| Lobbyist | Covered position, as disclosed |
|---|---|
| KATHLEEN JAEGER New | — |
Homeland Security HOM
IPA champions a U.S.-India trade partnership to drive national security and de-risk the affordable medicine supply chain, including Key Starting Materials (KSMs) and Active Pharmaceutical Ingredients (APIs). This initiative aims to extend to other trusted allies, enhancing global supply chain resilience.
Foreign entity interest: IPA is a trade association based in India, representing global manufacturers of both innovative and affordable medicines.
| Lobbyist | Covered position, as disclosed |
|---|---|
| KATHLEEN JAEGER New | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.